A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Launched by BERNIE EIGL · Nov 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to check for specific genetic changes in patients with metastatic bladder cancer, which is cancer that has spread to other parts of the body. The usual method involves taking a sample of tumor tissue, but this trial is exploring whether a blood test can provide more accurate results. By comparing the genetic information from both the blood and tissue samples, researchers hope to find out if more patients can benefit from a treatment called erdafitinib, which is designed for those with these genetic changes.

To participate in this trial, patients must have metastatic bladder cancer and be scheduled for standard tumor tissue testing for FGFR mutations. It's important to note that patients who will not have tissue samples sent for testing cannot join the study. Those who take part will have their blood drawn, and their results will be compared to the tissue test to see if the blood test can identify more patients who could be helped by the new treatment. This study is currently recruiting participants of all genders, aged 65 to 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis.
• Exclusion Criteria:
• • Metastatic bladder cancer patients who will not have tissue sent for FGFR testing will be excluded from this study.